Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GARDASIL Vaccine Impact in Population Study.

Next Previous
Trial Profile

GARDASIL Vaccine Impact in Population Study.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Female genital diseases; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Acronyms VIP
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 16 May 2018 Results assessing the prevalence of human papillomavirus infections before and after introduction of quadrivalent HPV vaccination, published in the Vaccine
    • 12 Dec 2015 Change in Time Frame after Gardasil licensure:- changed from 2011-2012 to 2007-2011. Patient ages also specifically mentioned in the timepoints as per ClinicalTrials.gov record.
    • 01 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top